Literature DB >> 18973295

Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes.

Jasna Maksimoska1, Li Feng, Klaus Harms, Chunling Yi, Joseph Kissil, Ronen Marmorstein, Eric Meggers.   

Abstract

A strategy for targeting protein kinases with large ATP-binding sites by using bulky and rigid octahedral ruthenium complexes as structural scaffolds is presented. A highly potent and selective GSK3 and Pim1 half-sandwich complex NP309 was successfully converted into a PAK1 inhibitor by making use of the large octahedral compounds Lambda-FL172 and Lambda-FL411 in which the cyclopentadienyl moiety of NP309 is replaced by a chloride and sterically demanding diimine ligands. A 1.65 A cocrystal structure of PAK1 with Lambda-FL172 reveals how the large coordination sphere of the ruthenium complex matches the size of the active site and serves as a yardstick to discriminate between otherwise closely related binding sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973295      PMCID: PMC2654244          DOI: 10.1021/ja805555a

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  8 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition.

Authors:  Nancy H Tran; Jeffrey A Frost
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157

3.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors.

Authors:  Howard Bregman; Patrick J Carroll; Eric Meggers
Journal:  J Am Chem Soc       Date:  2006-01-25       Impact factor: 15.419

Review 4.  p21-activated kinases in cancer.

Authors:  Rakesh Kumar; Anupama E Gururaj; Christopher J Barnes
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

5.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Authors:  Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson
Journal:  Chem Biol       Date:  2008-04

6.  Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins.

Authors:  J A Frost; H Steen; P Shapiro; T Lewis; N Ahn; P E Shaw; M H Cobb
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

7.  Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch.

Authors:  M Lei; W Lu; W Meng; M C Parrini; M J Eck; B J Mayer; S C Harrison
Journal:  Cell       Date:  2000-08-04       Impact factor: 41.582

8.  Structural bioinformatics-based design of selective, irreversible kinase inhibitors.

Authors:  Michael S Cohen; Chao Zhang; Kevan M Shokat; Jack Taunton
Journal:  Science       Date:  2005-05-27       Impact factor: 47.728

  8 in total
  41 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

Review 2.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

Review 3.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

Review 4.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

5.  Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors.

Authors:  Sebastian Blanck; Thomas Cruchter; Adina Vultur; Radostan Riedel; Klaus Harms; Meenhard Herlyn; Eric Meggers
Journal:  Organometallics       Date:  2011-07-18       Impact factor: 3.876

6.  The art of filling protein pockets efficiently with octahedral metal complexes.

Authors:  Sebastian Blanck; Jasna Maksimoska; Julia Baumeister; Klaus Harms; Ronen Marmorstein; Eric Meggers
Journal:  Angew Chem Int Ed Engl       Date:  2012-03-01       Impact factor: 15.336

7.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

8.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

9.  Studies of the Antiproliferative Activity of Ruthenium (II) Cyclopentadienyl-Derived Complexes with Nitrogen Coordinated Ligands.

Authors:  Virtudes Moreno; Julia Lorenzo; Francesc X Aviles; M Helena Garcia; João P Ribeiro; Tânia S Morais; Pedro Florindo; M Paula Robalo
Journal:  Bioinorg Chem Appl       Date:  2010-06-20       Impact factor: 7.778

10.  From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors.

Authors:  Nicholas Pagano; Eric Y Wong; Tom Breiding; Haidong Liu; Alexander Wilbuer; Howard Bregman; Qi Shen; Scott L Diamond; Eric Meggers
Journal:  J Org Chem       Date:  2009-12-04       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.